Neural Therapeutics CEO Addresses Revolutionary Effects of Psychedelic Medicine
Neural Therapeutics CEO Ian Campbell addresses the potential of psychedelic medicine in transforming mental illness treatment and addressing the opioid crisis, emphasizing the lack of addictive properties in the substances developed by the company.
The news highlights the potential of psychedelic medicine in transforming mental illness treatment and addressing the opioid crisis. It emphasizes the lack of addictive properties in the substances developed by Neural Therapeutics, offering hope for effective treatment of substance use disorders.
